Therapeutic approaches to Alzheimer's disease

被引:264
作者
Klafki, Hans-Wolfgang
Staufenbiel, Matthias
Kornhuber, Johannes
Wiltfang, Jens
机构
[1] Univ Erlangen Nurnberg, Dept Psychiat & Psychotherapy, D-91054 Erlangen, Germany
[2] Novartis Inst Biomed Res, Basel, Switzerland
关键词
amyloid plaques; neurofibrillary tangles; tau pathology; therapeutic strategies;
D O I
10.1093/brain/awl280
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Alzheimer's disease is an age-related progressive neurodegenerative disorder with an enormous unmet medical need. It is the most common form of dementia affecting similar to 5% of adults over 65 years. In view of our ageing society the number of patients, as well as the economical and social impact, is expected to grow dramatically in the future. Currently available medications appear to be able to produce moderate symptomatic benefits but not to stop disease progression. The search for novel therapeutic approaches targeting the presumed underlying pathogenic mechanisms has been a major focus of research and it is expected that novel medications with disease-modifying properties will emerge from these efforts in the future. In this review, currently available drugs as well as novel therapeutic strategies, in particular those targeting amyloid and tau pathologies, are discussed.
引用
收藏
页码:2840 / 2855
页数:16
相关论文
共 243 条
[11]   Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy [J].
Backskai, BJ ;
Kajdasz, ST ;
Christie, RH ;
Carter, C ;
Games, D ;
Seubert, P ;
Schenk, D ;
Hyman, BT .
NATURE MEDICINE, 2001, 7 (03) :369-372
[12]  
Bacskai BJ, 2002, J NEUROSCI, V22, P7873
[13]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[14]   Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology [J].
Bard, F ;
Barbour, R ;
Cannon, C ;
Carretto, R ;
Fox, M ;
Games, D ;
Guido, T ;
Hoenow, K ;
Hu, K ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, C ;
Lee, M ;
Motter, R ;
Nguyen, M ;
Reed, A ;
Schenk, D ;
Tang, P ;
Vasquez, N ;
Seubert, P ;
Yednock, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :2023-2028
[15]   THE CHOLINERGIC HYPOTHESIS OF GERIATRIC MEMORY DYSFUNCTION [J].
BARTUS, RT ;
DEAN, RL ;
BEER, B ;
LIPPA, AS .
SCIENCE, 1982, 217 (4558) :408-417
[16]   Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD [J].
Bayer, AJ ;
Bullock, R ;
Jones, RW ;
Wilkinson, D ;
Paterson, KR ;
Jenkins, L ;
Millais, SB ;
Donoghue, S .
NEUROLOGY, 2005, 64 (01) :94-101
[17]  
BICK KL, 1994, ALZHEIMER DIS
[18]   Intraneuronal Aβ causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice [J].
Billings, LM ;
Oddo, S ;
Green, KN ;
McGaugh, JL ;
LaFerla, FM .
NEURON, 2005, 45 (05) :675-688
[19]  
Birks J, 2006, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001190.pub2, 10.1002/14651858.CD001190.pub3]
[20]   Rivastigmine for Alzheimer's disease [J].
Birks, Jacqueline S. ;
Evans, John Grimley .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2015, (04)